Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
Garber
Ken
K
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D035843:Biomedical Research; D015195:Drug Design; D004345:Drug Industry / Q000458:organization & administration* / Q000639:trends; D015507:Drugs, Investigational / Q000494:pharmacology; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005858:Germany; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D014481:United States; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D016228:Endothelial Growth Factors; D007211:Indoles; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D011758:Pyrroles; D011799:Quinazolines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C116890:Semaxinib; D000069347:Erlotinib Hydrochloride